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A promoter polymorphism of the osteopontin (OPN) gene (rs28357094) has been associated with multiple inflammatory states, severity of Duchenne muscular dystrophy (DMD) and muscle size in healthy young adults. We
sought to define the mechanism of action of the polymorphism, using allele-specific in vitro reporter assays
in muscle cells, and a genotype-stratified intervention in healthy controls. In vitro reporter constructs showed
the G allele to respond to estrogen treatment, whereas the T allele showed no transcriptional response.
Young adult volunteers (n 5 187) were enrolled into a baseline study, and subjects with specific rs28357094 genotypes enrolled into an eccentric muscle challenge intervention [n 5 3 TT; n 5 3 GG/GT (dominant inheritance
model)]. Female volunteers carrying the G allele showed significantly greater inflammation and increased
muscle volume change as determined by magnetic resonance imaging T1- and T2-weighted images after eccentric challenge, as well as greater decrement in biceps muscle force. Our data suggest a model where the G allele
enables enhanced activities of upstream enhancer elements due to loss of Sp1 binding at the polymorphic site.
This results in significantly greater expression of the pro-inflammatory OPN cytokine during tissue remodeling
in response to challenge in G allele carriers, promoting muscle hypertrophy in normal females, but increased
damage in DMD patients.

INTRODUCTION
Genetic association studies are a powerful tool to identify regions
of the human genome associated with specific traits, both in health
and disease. A limitation of the approach is the challenges frequently associated with defining the biochemical and physiological consequences of the genetic variants. We hypothesized
that targeted interventions in genotype-stratified healthy volunteer groups could provide a means of testing molecular models
for specific polymorphisms.
A common polymorphism in the transcriptional promoter
of the osteopontin (OPN) gene (rs28357094) has been found
to be a strong genetic modifier of muscle size in young adult
volunteers (1), and muscle weakness and disease progression
in Duchenne muscular dystrophy (DMD) (2). Both studies
showed a dominant inheritance model of the polymorphism

effect on phenotypes (TT versus GG/GT genotype groups).
The T-to-G single nucleotide polymorphism (SNP) is located
66 bp upstream of the OPN transcription initiation site overlapping a specificity protein-1 (SP1) transcription factor-binding
site. The minor G allele has shown to significantly inhibit
the binding of SP1, and this loss of binding results in an 80%
reduction in transcriptional activity in multiple human
immortalized cell lines (3). The same rs28357094 polymorphism has been associated with predisposition to autoimmune
disorders including systemic lupus erythematosus and juvenile
dermatomyositis (4,5).
Osteopontin is an acidic glycoprotein that is a member of the
small integrin binding N-linked glycoprotein family that is involved
in several biological pathways (6–8). OPN is viewed as an inflammatory cytokine that promotes cellular activation, migration
and chemotaxis. The protein has an arginine–glycine–aspartate-
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binding domain, an adjacent SVVYGLR motif showing potent
angiogenic properties (9) and CD44 receptor-binding affinity that
allows it to interact with a diverse range of cells (10). It has been extensively studied in a number of physiological processes including
bone remodeling, tissue repair, wound healing, autoimmune disorders and numerous inflammatory conditions (11–13).
The OPN protein is at very low or undetectable levels in normal
skeletal muscle. However, induction of muscle damage results in
a 100-fold increase in OPN gene transcription (1,14). Muscles
from Duchenne muscular dystrophy patients, as well as the
dystrophin-deficient dog and mouse models also show very high
levels of OPN mRNA and protein, consistent with chronic inflammation and myofiber degeneration/regeneration observed in these
muscles (2,15). High OPN expression in pre-natal diaphragm of
the dystrophin-deficient dogs has been seen in CD11b infiltrating
cells prior to post-natal necrosis, and was considered an early
biomarker of dystrophin deficiency (16). OPN is considered
a pro-inflammatory cytokine in muscle, where it serves as a
chemoattractant for macrophages (14), and possibly neutrophils
(13), and studies of double knockouts of dystrophin and OPN
suggest that OPN can be deleterious to muscle remodeling (17).
However, during normal muscle damage and repair, OPN is
important for effective neutrophil and macrophage recruitment,
clearing of necrotic cells and effective regeneration (18). Thus,
increased OPN expression in muscle is seen in both normal and
pathological muscle remodeling, and may serve both a normal
physiological role and a pathological role (as is the case for
many TGFbeta-associated proteins).
The genetic association of the OPN gene promoter polymorphism, rs28357094, with 17% increase in muscle size in
healthy young adult females (1), and muscle wasting and weakness in Duchenne muscular dystrophy patients (2) was consistent
with an important role of the OPN protein in modulating muscle
response to damage and remodeling. However, the effect of the
polymorphism on gene expression was difficult to rationalize
with the observed phenotype associations. Specifically, the G
allele has been shown to cause a 80% reduction in OPN gene promoter activity, and the same G allele was associated with a more

severe DMD phenotype in young boys, and larger muscle in
female (and not male) adult volunteers. To develop a molecular
model for the effect of the polymorphism on muscle, we carried
out both in vitro studies of the OPN gene promoter using reporter
assays and in vivo studies of an eccentric muscle challenge in
adult female volunteers. The in vitro assays used site-directed
mutagenesis to remove the possible effects of additional polymorphisms that may be in linkage disequilibrium with the
rs28357094 locus and studied estrogen responsiveness of the different alleles. OPN has been previously reported to be estrogen
responsive, and the gene promoter contains estrogen-response
elements (EREs) (19,20), but the possible interactions of
the ERE and the rs28357094 have not been previously studied.
Our data show a strong effect of the polymorphism on the
response of the OPN gene to estrogen, and the in vitro and
in vivo data presented are consistent with a novel molecular
model that explains the effects of OPN on muscle remodeling.

RESULTS
The 266 bp OPN polymorphism shows differential effects
on baseline and estrogen-responsive transcriptional
regulation in muscle cells
Allele-specific OPN promoter fragments (2899 to +109 bp)
were cloned into pGL4.15 luciferase reporter vectors to
examine the effects of the 266 bp T/G SNP on OPN promoter
activity. The constructs were then transfected into human skeletal
muscle myoblasts, and baseline luciferase activity was then determined. The minor G allele caused an 80% reduction in baseline
luciferase expression in transfected cells compared with the
ancestral T allele (Fig. 1A). These results correspond to established data that suggest that the G allele causes a significant reduction in OPN expression (3).
Cells transfected with the allele-specific constructs were then
treated with 100 nM of estrogen in serum-free media and a luciferase assay was performed 24 h after the estrogen treatment
(Fig. 1B). Myoblasts transfected with constructs containing the

Figure 1. The G allele of the rs28357094 polymorphism shows decreased basal promoter activity, but higher transcriptional response to estrogen hormone treatment.
(A) Allele-specific promoter reporter constructs were transfected into human myoblasts and assayed for baseline luciferase expression. The G allele showed an 80%
reduction in baseline expression (P , 0.001), consistent with previous reports of loss of Sp1 binding and lower baseline expression in other cell types (3). (B) The same
constructs were then tested in the presence of estrogen (100 nM). The T allele construct was unresponsive to estrogen, while the G allele construct showed a 3-fold
increase in luciferase expression (P , 0.001).
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Table 1 Participants in the eccentric muscle challenge intervention
ID

OPN
genotype

Age
(years)

Height
(cm)

Weight
(lbs)

Neck circumference
(cm)

Mid-waist
circumference (cm)

Hip circumference
(cm)

BMI
(lbs/in2)

Eccentric
exercise reps

101
102
103
104
105
106

GG
TT
GG
TT
GT
TT

23
20
19
19
21
21

171.9
176.0
168.9
175.0
171.9
178.1

251.8
223.9
186.9
202.3
172.8
160.8

14.3
14.5
13.8
nd
13.2
13.3

41.1
41.7
32.9
nd
32.9
30.2

50.1
44.0
45.8
nd
45.9
39.2

38.6
32.8
29.7
30.0
26.5
23.0

11
16
10
10
12
16

Phenotypic features of the six AA females participating in the eccentric challenge intervention are shown. One participant (104) declined some measurements
(nd, not done).

Figure 2. Protocol design for eccentric contraction challenge of the biceps
muscle in young adult female volunteers. Initial visits were for informed
consent, anthropomorphic measures and assessments of baseline phenotypes
including MRI of both the dominant and non-dominant upper arm. Eccentric
challenge of the non-dominant arm was at visit 4 (Day 0) with exit MRI at
Day 4. Eccentric challenge was done only once on visit 4 (Day 0), with all subsequent visits done to assess the delayed effects of this challenge on strength
and MRI changes.

G allele and treated with estrogen showed a 3-fold increase in luciferase activity compared with untreated cells. Cells transfected
with constructs containing the T allele did not show any significant
differences in expression when treated with estrogen (Fig. 1B).
Eccentric exercise challenge in AA adult females
Subjects were enrolled into the Assessing Inherited Metabolic
Markers in the Young (AIMM Young) at Howard University
(21). As part of the AIMMY IRB consent, subjects were asked
if they could be re-contacted for future studies. Genomic
DNAs of 187 African-American (AA) participants in the AIMM
Young study were genotyped for the 266 T/G OPN variant
(rs28357094). The G allele showed an allele frequency of 8.8%
in the AA group, with 17% of subjects showing GT or GG genotype (dominant inheritance model). The allele frequency observed
in the AA participants was about half that observed in Caucasian
populations (1). We limited the current study to the analysis of
young adult females due to the female-specific effect of genotype
in our previous studies of young adult Caucasian college students
(1). Of the 23 AA females with the minor G allele, 14 were
re-contacted and 6 females volunteered for the eccentric challenge
protocol (3 GG/GT and 3 TT) (demographics in Table 1).
The eccentric challenge protocol consisted of nine visits
(Fig. 2). The initial visit included a description of the proposed
study, informed consent, anthropometric assessments and DXA.
Although individuals were from a population-based recruitment
strategy, five out of six of the participants had a BMI .26 categorizing them as overweight or obese (Table 1); however, this
reflected the overall AA female student population as we recently
described (21). Visit 2 included a baseline magnetic resonance
imaging (MRI) of upper arm of both the dominant and

non-dominant arms. All MRI assessments were done using a
pre-formed cast set at 1208 angle, and images obtained in a knee
coil. All images were done on the same MRI unit by the same
staff. Visits 3 and 4 consisted of assessments of baseline isometric
strength test and baseline pain assessments.
The eccentric muscle challenge was done at visit 4 (Day 0 for
post-challenge assessments; Fig. 2) as previously described (22).
The subject was positioned with their non-dominant arm at 908
angle and then instructed to resist extension of the arm with
maximal voluntary elbow (biceps) contraction, with the extension
force generated by the evaluator with a bar and chain connected to
the modified preacher’s bench. The arm was gradually lengthened
from 908 to 1808 over a 5 s time. Repeated bouts were done with a
15 s rest period between bouts, until exhaustion (fatigue; average
12 bouts) (Table 1). Measures of isometric strength test were done
for both the non-dominant (eccentric bout) and dominant (nonexercised) arms for 4 consecutive days following the intervention.
Assessments of pain were also done at each visit. The post-bout
MRI was done subsequent to baseline strength and pain assessments, 4 days after the bout of eccentric contractions (visit 9)
(Fig. 2). This time point was previously shown to exhibit the greatest degree of muscle swelling (22).
The G allele is associated with greater loss of strength after
eccentric challenge
Measures of isometric strength test were done before the bout,
and at each of 4 days after the bout on both the exercised nondominant arm and non-exercised dominant arm. Volunteers
with the common TT genotype showed a time-related drop in
force of the exercised non-dominant arm, but also showed a
drop in the non-exercised arm such that the difference in arms
was not significant (Fig. 3A). The volunteers carrying the G
allele showed a more substantial drop in force of the exercised
non-dominant arm, whereas the non-exercised arm showed no
decrease in strength (Fig. 3B). The difference in percentage
drop in force between the exercised and non-exercised arms
for the G allele carriers was highly statistically significant considering both d0-d2 (P , 0.001) and d0-d4 (P , 0.001) as was
the interaction between time and arm (P ¼ 0.02).
The G allele is associated with greater muscle swelling and
inflammation
T2 images were taken of both dominant and non-dominant arms
before the eccentric challenge and 4 days after the challenge.
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Figure 3. Measures of maximal isometric strength in genotype-stratified young
adult female volunteers. Isometric strength of both the non-dominant arm (eccentric bout) and dominant arm (non-exercised control) was measured in TT homozygotes (n ¼ 3) (A), and G allele carriers (GG and GT; n ¼ 3) (B). Pre is prior to
the eccentric exercise challenge, with measures then subsequent days after the
bout. TT homozygotes showed a small drop in force that was similar in both
arms (A). G allele carriers showed a 40% drop in muscle strength in the exercised
arm (P , 0.001), with a small increase in strength in the non-exercised arm (B).

The non-exercised dominant arm showed similar features in all
subjects, with no evidence of inflammation or muscle swelling
(Figs 4 and 5). In the TT genotype volunteers, the post-exercise
non-dominant arm showed hyper-intense regions of the biceps
evident in OPN-102 and OPN-106 (Fig. 4, white arrows).
Subject OPN-104 showed no obvious hyper-intense T2 regions.
In the G allele carriers, there was striking hyper-intense regions
involving the majority of the biceps in all three subjects (Fig. 5,
white solid arrows). In two of the subjects (OPN-103, OPN-105)
there was markedly hyper-intense regions at the ventral region
of the biceps extending into the underlying subcutaneous fat
(Fig. 5, stippled arrows). The area of inflammation appeared centered on the brachial artery and included apparent increased T2
signal in the veins and arteries, but not the brachial plexus.
The cross-sectional area of each biceps muscle was determined
and the percent change in area of the exercised non-dominant arm
determined between the pre-challenge and post-challenge images
(Fig. 6). The TT homozygote subjects showed an average of 3%
increase in biceps cross-sectional area, whereas the G allele carriers showed an average of 15% increase in size. The difference
in swelling between the TT and G genotype carriers was statistically significant (P , 0.05).

Figure 4. T2-weighted MRI images of young adult female volunteers having TT
OPN genotype. Shown are MRI T2-weighted images of the non-dominant upper
arm prior to eccentric challenge (pre-challenge) and 4 days after eccentric challenge (post-challenge). Subjects OPN-102 and OPN-106 show areas with an
increase of T2 signal in the biceps in the post-challenge images consistent with
increased water content (swelling) (white arrows). Areas of hyper-intensity
were not evident in OPN-104.

DISCUSSION
The goal of our study was to provide in vitro and in vivo data sufficient to build a unifying model for the action of the 266 bp T/G
polymorphism in the Sp1 transcription factor-binding site of the
OPN gene promoter in muscle. Our previous findings had presented somewhat of an enigma, where the G allele was associated
with larger muscle volume in young adult volunteer females (1),
yet weaker muscles in young DMD boys (2). Moreover, previous
studies had shown the G allele to result in 80% loss of OPN
gene expression in different human immortalized cell lines (3),
suggesting that less OPN (an inflammatory cytokine) results in
larger muscles in females, yet weaker muscles in DMD boys.
Testing of allele-specific reporter constructs in human muscle
cells confirmed previous findings in other cell types, with a
loss of 80% of promoter strength (Fig. 1A).
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Figure 6. Percent volume change in biceps muscles after an acute eccentric exercise bout. Biceps muscle volume change was measured from MRI images in the
exercised arm of genotype-stratified subjects at Day 4 after the bout of eccentric
challenge. G allele carriers showed greater biceps swelling compared with TT
homozygotes (P , 0.05).

Figure 5. T2-weighted MRI images of young adult females carrying the G allele
of the OPN promoter polymorphism. Shown are MRI images using the same
methods and time points as in Figure 4. The three subjects carrying the G allele
show extensive hyper-intensity throughout much of the biceps muscle (white
solid arrows). Subjects OPN-103 and OPN-105 also show evidence of inflammation (stippled arrows) surrounding the brachial artery/nerve area. The inflammation extended into the biceps, and also into the ventral subcutaneous fat tissue.

Our search of the OPN gene promoter for enhancer elements
found potential enhancer sequences for multiple steroid hormone-binding sites [estrogen receptor (2674 bp), glucocorticoid
receptor (2926 bp), vitamin D receptor (21877 bp)], as well as
a potential Nuclear factor kappa beta (NFkB) binding site
(21162 bp) (Fig. 7). Given the female-specific effect of the promoter polymorphism on muscle size, we hypothesized that there
may be an allele-specific interaction between the estrogen enhancer and the more proximal Sp1 transcription factor site. Indeed,
treatment of muscle cells with allele-specific reporter constructs
showed that estrogen induced a 3-fold increase over baseline for
the G allele, but no change in expression for the T allele (Fig. 1B).
These data suggest a hypothetical model for the sex-specific
effects of the polymorphism on muscle size in females. High
estrogen levels in young adult females lead to increased
damage-induced OPN levels in G allele carriers due to lack of residency of the more proximal Sp1 transcription factor binding. On

the other hand, T allele homozygotes have the estrogen (and
possibly NFkB) response blocked due to residency of the Sp1
transcription factor near the mediator complex (Fig. 7). This
model predicted that young adult females carrying the G allele
may show greater sensitivity to muscle damage, and the muscle
damage may in turn cause more hypertrophy in these women.
Bouts of eccentric muscle activity (lengthening contractions)
are known to induce mild muscle damage and stimulate muscle
hypertrophy. We hypothesized that a bout of eccentric activity in
young adult females stratified for OPN genotype would show a
differential response to an eccentric bout, with the G allele carriers showing greater inflammation and swelling. To test this,
female volunteers were recruited from the AIMM Young baseline genotype/phenotype study of young adults (21). Three
females of each genotype undertook an eccentric exercise bout
of the non-dominant upper arm (biceps), with longitudinal measures of strength and imaging by MRI. This study confirmed our
hypothesis. The G allele carriers showed significantly greater
muscle swelling at Day 4 after the bout and greater loss of
strength (Figs 3 – 6). Surprising, there was striking inflammatory
signal in the MRI in two of the three G allele carriers, centered on
the brachial large blood vessels (Fig. 5). The inflammation
extended into the biceps, but also into the subcutaneous fat
ventral to the brachial complex.
Our model suggests that G allele carriers show heightened
sensitivity to mild muscle damage, with both exaggerated
muscle swelling and inflammatory response, and this leads to
greater susceptibility to muscle hypertrophy. In Duchenne muscular dystrophy, patient muscle shows a high degree of activation of
NFkB pro-inflammatory pathways soon after birth, many years
prior to clinical onset (23). Given the promoter structure of the
OPN gene, with multiple predicted steroid hormone enhancers
and NFkB promoter element (Fig. 7), our model can be extended
to the observed genotype/phenotype relationship in DMD.
DMD patients carrying the G allele may show greater NFkBand/or glucocorticoid-induced transcription of the OPN gene
during chronic inflammation, leading to exacerbation of the
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Figure 7. Schematic of the OPN gene promoter structure, and proposed model for effect of genotype on OPN gene expression. The top two lines show the OPN gene
promoter structure and proposed model for the allele-specific effects of the rs28357094 polymorphism (266T, 266G) on transcriptional regulation of the OPN gene.
The 266 T allele is shown to have high basal expression, but blocks positive transcriptional response to the estrogen enhancer due to residency of the SP1 transcription
factor in the intact SP1-binding site (top line of figure). The 266G allele shows reduced basal expression, but is highly responsive to estrogen due to loss of the
SP1-binding site (second line of figure) (3). The predicted enhancer elements are in the more distal regions of the OPN gene promoter (VDRE, vitamin D receptor
element; GRE, glucocorticoid response element; ERE, estrogen response element). The lower line of the figure shows the allele-specific reporter constructs used
for transfection of human muscle cells. The genotype/phenotype associations of this polymorphism with muscle phenotypes have shown data consistent with a dominant model of inheritance, with two genotype groups (TT and GT + GG).

pro-inflammatory state of muscle and worsening of phenotype,
as we have previously reported. Thus, the integration of gene
structure, in vitro reporter assays and intervention study in
young adult volunteers provides a hypothetical unifying model
for the interaction of the OPN promoter SNP and muscle remodeling. However, the complex regulation of the OPN gene in
response to multiple inflammatory and steroid hormone
promoter elements makes it challenging to predict the precise
responses of the gene in vivo.
Limitations to the study presented here include the low
number of volunteers enrolled into the eccentric intervention
(n ¼ 3 per genotype group), and the lack of muscle biopsies
from the volunteers to correlate OPN protein and mRNA
levels with respective genotypes and degree of inflammation.
Extensive correlations of OPN genotype with OPN protein
levels have been previously reported for DMD patient muscle,
and there was no association of genotype with OPN levels
(24). The argument presented in this previous publication is
that the variable degree of inflammation in each biopsy and
complex regulation of OPN protein in the extracellular space,
both likely obscures the in vivo correlations of OPN genotype
and OPN gene expression seen in vitro. Finally, we have not directly addressed the molecular basis of the association of the G
allele with muscle weakness in DMD. Our results suggest that
this association may be related to glucocorticoid treatment of

DMD, but further genetic associations studies of DMD patient
populations treated and un-treated with glucocorticoids must
be done to test this hypothesis.

MATERIALS AND METHODS
Human subjects
One hundred and eighty-seven AA females previously recruited
into the NIH P20 AIMM Young Study from Howard University
were genotyped for the rs2857094 polymorphism. AIMM
Young is an ongoing project that concentrates on the genetics
of metabolic syndrome in young adults (21). It functions as a
collaborative between the Georgetown-Howard Universities
Center for Clinical and Translational Science and Children’s National Medical Center. AIMM Young subjects were re-contacted
based on genotype and asked to complete an eccentric muscle
challenge with MRI as the final outcome. A total of six females
(3 GG/GT and 3 TT) were subsequently enrolled into the eccentric
exercise intervention. All females were 19–23 years of age,
healthy and either sedentary or only recreationally active. Participants were screened prior to study entry to determine if they had
any orthopedic, muscular or other medical conditions that
would prohibit them from completing the study.

Human Molecular Genetics, 2014, Vol. 23, No. 15

Genotyping
To determine the specific OPN genotype of rs28357094 (266 T/G
variant), DNA was extracted from the peripheral blood of all 187
individuals within the Howard University AIMM Young Study
using standard manufacturer’s procedures (Qiagen, Valencia,
CA, USA). DNA was then amplified on an ABI 2720 Thermal
Cycler using TaqMan rs28357094 primers/probe: forward
5′ -AAGTGCTCTTCCTGGATGCTG-3′ , reverse 5′ -CTCCTGC
TGCTGCTGACAAC-3′ and sickle cell probe rs334: forward
5′ -AGTCAGGGCAGAGCCATCTA-3′ , reverse 5′ -CTCACCA
CCAACTTCATCCA-3′ .
Biceps isometric strength test
Participants performed isometric strength test of the biceps
muscles using a modified arm curl bench (CSN Stores, MA,
USA). To assess biceps flexion isometric strength, the arm was
positioned at a 908 angle with the curl bar attached to a load
cell (Transducer Technologies, Inc., Whittier, CA, USA).
During the test the subject was instructed to exert a maximal
biceps muscle contraction at the 908 angle and the tension
generated was recorded as maximal strength expressed in kilograms. Muscle strength was assessed in both the right and left
arms with the subjects performing three maximal contractions
on each arm. All statistical analyses utilized the average value
for these three strength measurements.
Exercise protocol
Each participant performed one set of maximal lengthening contractions (eccentric) on a modified preachers arm curl machine.
The eccentric exercise protocol has been detailed previously
(22). To perform this exercise, the active arm of the participant
was placed on the padded support in a flexed position, while
the passive arm rested on the participant’s side. The participant’s
arm was then guided by the investigator from a completely flexed
position to a fully extended position. The modifications in the
preacher’s bench allowed for maximal resistance to the participant throughout the entire range of motion. Each contraction
lasted 5 s and was repeated every 15 s. The participant’s
arm was then brought back to the flexed position to prevent concentric muscle contractions. The procedure was repeated a
maximum of 24 times or until the participant fatigued. Subsequent isometric strength tests and a 25 ml blood sample were
obtained.
Magnetic resonance imaging
The MRI procedure was performed on a GE Signa HDxt 3.0T
High-Field System (General Electric Company, CT, USA)
using a GE Signa HDxt 3.0T HD Knee coil (General Electric
Company). The participant was placed laterally with arm
placed into a plastic mold to secure it comfortably at a 1208
angle in the knee coil, and ensure reliability from subject to
subject regarding placement of the arm and related images.
64—4 mm slices were taken because of the broad limit of the
long axis of the knee coil (256 mm). In a coronal view, the
slice direction was parallel to the humerus plane and the fourth
slice was precisely placed at the vertex of elbow point. In a
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sagittal view, the slice direction was parallel to the humerus
plane. The region of interest (ROI) was adjusted to cover the
area from the elbow joint to the limit of the knee coil. The
imaging sequence used in the T1-weighted upper arm scan
was a Fast Spin Echo sequence: TE ¼ 6 ms, TR ¼ 1000 ms,
echo train ¼ 6, FOV ¼ 14 cm, matrix ¼ 320 × 224, slice
thickness ¼ 4 mm, slice gap ¼ 0 mm, 64 slices. Two sets of
double-echo sequences were used to get the T2 fat suppression
images at TE ¼ 7.1, 40, 70, 90 ms. Fast spin echo sequences:
(1) acquisition: the TE ¼ 7.1 and 70.1 ms. Parameters: TE ¼
7.1 and 70.1 ms, TR ¼ 4467 ms, echo train ¼ 18, FOV ¼
14 cm, matrix ¼ 256 × 192, slice thickness ¼ 4 mm, slice
gap ¼ 0 mm, 64 slices. (2) Acquisition: the 40 and 90 ms. Parameters were the same as the 7.1 and 70.1 ms parameters.
After retrieving scans, the total biceps region was identified on
T1-weighted images and the area was outlined using ImageJ
software. The scans were adjusted so that identical regions
were compared each time. ‘Muscle volume’ was defined as the
total pixilated region of the outlined area in millimeters. The
swelling post-exercise was determined by comparing changes
in muscle volume between MRI scans at study entry and posteccentric exercise.
Plasmid constructs
Osteopontin promoter fragment from 2899 to +109 was prepared by PCR amplification from genomic DNA of homozygous
individual, cloned into pGL4.15 [luc2P/Hygro] vector (Promega,
Medison, WI, USA) and the inserted sequence was verified
by Switchgear genomics (Menlo Park, CA, USA). Site-directed
mutagenesis was performed according to manufacturer’s instruction (Agilent Technologies, Santa Clara, CA, USA) to obtain
single site-specific mutation construct at position 266 bp of the
promoter region of OPN (T–G). The primers used for the sitedirected mutagenesis were as follows: sense primer 5′ -CCCA
AGGTTGCACAGTTCAGCAGTGACACAG-3′ and antisense
primer 5′ -GGGTTCCAACGTGTCAAGTCGTCACTGTGTC-3′ .
Cell culture and transfection
Human skeletal myoblast cell line (obtained from Vincent
Mouly, Institut de Myologie, Paris, France) was maintained in
skeletal muscle cell growth medium using skeletal muscle cell
growth medium kit (Promocell, Heidelberg, Germany) supplemented with 20% fetal calf serum and penicillin – streptomycin
(1% (v/v); all supplied by Life Technology, Carlsbad, CA,
USA). Cultures were maintained in this complete growth
medium in a humidified atmosphere under 5% CO2 at 378C.
Cell transfection was performed using Lipofectamine LTX
(Life Technology) according to manufacturer’s instruction.
Cells were plated into 6-well plates at 70– 80% confluence.
Transfection was performed over a 48 h period in complete
growth medium without antibiotic. The amount of DNA used
for transfection was 2.5 mg. In the experiments where estrogen
(Sigma-Aldrich, St. Louis, MO, USA) was added, the complete
growth medium with transfection reagent was removed; cells
were washed and replaced with serum-free medium containing
100 nM estrogen for further 24 h. Cell lysates were prepared
using lysis buffer consisting of 25 mM Gly (pH 7.8), 1% Triton
X-100 (v/v), 15 mM MgSO4 (heptahydrate), 4 mM EGTA and
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1 mM DTT in 10 ml water. Luciferase activity was measured
using Luciferase Assay system (Promega) with Centro LB 960
microplate luminometer (Berthold Technologies, Oak Ridge,
TN, USA). The data obtained were normalized to the protein
concentration from each well.
Statistical analysis
Several phenotypes were compared with tests appropriate for
the distribution of the dependent variable. A P-value of ≤0.05
was considered statistically significant. As shown in Figure 1,
the comparison of % decrease in luciferase activity between
TT and G allele cells were performed using a student’s t-test
and the comparison of fold change between baseline and postestrogen treatment was performed in TT and G allele cells
separately using a paired t-test. Analyses comparing changes
in isometric strength between arms (Fig. 3) were performed
using a repeated-measure ANOVA including main effects of
arm and time and an arm × time interaction. Lastly, the comparison between median % change in muscle volume between TT
and G allele individuals was performed using a Wilcoxon rank
sum test.
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